Peptide-major histocompatibility complex class I from cytomegalovirus or Epstein-Barr virus

The CMV or EBV peptide–MHC complex consists of viral peptides derived from cytomegalovirus or Epstein-Barr virus proteins, loaded into the binding groove of class I or class II MHC molecules and displayed on the surface of infected or antigen-presenting cells[2][3][7]. These complexes are critical for recognition by T cell receptors, leading to cytotoxic T lymphocyte or helper T cell responses that are essential for viral clearance or immune monitoring. They are central to immunotherapeutic strategies where T cell receptors or TCR-mimic antibodies are engineered to target virally infected cells or virus-induced malignancies. As an entity, it is a functional immune complex rather than a single molecular drug target[3]. In summary: - The term is imprecise for a unique molecular target and covers a *broad class of viral peptides presented by MHC molecules*, which function as key signals to the adaptive immune system[5][6]. - It is *not* a unique or canonical molecular species; usage should specify the viral peptide and MHC allele involved for structured biomedical data.

Other names

CMV peptide-MHC complexEBV peptide-MHC complexViral peptide-MHC complex (CMV/EBV)Viral pMHC (CMV/EBV)Virus-derived peptide–major histocompatibility complex

TCR-mimic antibodies, or adoptive T cells, specifically recognize the CMV/EBV peptide–MHC complex on infected or malignant cells leading to cell lysis or immune activation